There are currently few studies on the association between arm venous port implantation and anxiety levels in colorectal cancer chemotherapy patients, and there is a lack of systematic analysis of related risk factors. Further research is urgently needed to provide scientific evidence for clinical practice. To investigate the risk factors for anxiety in patients with arm venous access ports after chemotherapy and established a predictive model. A total of 245 patients were enrolled in this study, among whom 94 patients developed anxiety symptoms after chemotherapy. The enrolled patients were randomly divided into a training set and a validation set in a 7:3 ratio, with 171 patients in the training set and 74 patients in the validation set. Demographic and disease-related data were collected from the patients. The study investigated the factors associated with anxiety after chemotherapy in patients with arm venous access ports and established a predictive model. Factors potentially associated with anxiety were included in a univariate logistic regression analysis. The results indicated that 5 factors – educational attainment, marital status, presence of a bedside companion, distant metastasis, and chemotherapy-related adverse reactions – had P values < .2, making them potential risk factors for anxiety in patients with an arm-based intravenous port following chemotherapy. Further analysis using a multivariate regression model revealed that marital status, presence of a bedside companion, distant metastasis, and chemotherapy-related side effects were identified as independent risk factors for post-chemotherapy anxiety in patients with an arm venous access port ( P < .05). This study confirmed that marital status, bedside companions, distant metastasis, and chemotherapy side effects are 4 independent risk factors for anxiety in patients with arm venous access ports after chemotherapy. The predictive model established in this study provides a powerful tool for clinicians to identify high-risk patients for post-chemotherapy anxiety at an early stage, enabling them to provide timely interventions such as symptomatic treatment and alleviation of chemotherapy side effects, thereby reducing the incidence of post-chemotherapy anxiety in patients.
Zhang et al. (Fri,) studied this question.